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Background: Cytological fluid from a needle aspiration biopsy (NAB) is obtained directly from tumor tissue,
therefore many biomarker candidates will be present in high concentrations. The aim of this study was to
prospectively assess and validate the tumor markers CYFRA 21–1, CEA, and SCC in cytological fluid obtained from
NAB samples to determine if they improved the performance of NAB for diagnosing non-small cell lung cancer
(NSCLC).
Methods: A total of 194 patients (M:F = 128:66, mean age 63.7 years) with suspected malignant pulmonary lesions
were prospectively enrolled and underwent percutaneous NAB. Levels of CYFRA 21–1, CEA, and SCC were
measured by immunoassay in serum and cytological fluid obtained during aspiration biopsy. Cut-off values to
determined malignancy were 3.3 ng/mL in serum and 15.7 ng/mL in cytological fluid for CYFRA 21–1, 5 ng/mL and
0.6 ng/mL for CEA, and 2 ng/mL and 0.86 ng/mL for SCC.
Results: Of 194 patients, 139 patients (71.6%) had NSCLC and 55 (28.4%) had benign lesions. Sensitivity increased
significantly for NAB combined with cytological tumor markers compared with NAB alone (CYFRA 21–1: 95% versus
83.5%, p < 0.001, CEA: 92.1% versus 83.5%, p = 0.002, SCC: 91.4% versus 83.5%, p = 0.003). Accuracy improved
significantly for NAB combined with cytological CYFRA 21–1 compared with NAB alone (95.9% versus 88.1%, p <
0.001). The area under curve (AUC) of NAB with cytological CYFRA 21–1 was significantly larger than for NAB alone
(0.966 versus 0.917, p = 0.009).
Conclusion: Of the tested tumor markers, cytological fluid measurements of CYFRA 21–1 improved the diagnostic
performance of NAB for NSCLC.
Keywords: Cytokeratin 19 fragments (CYFRA 21–1), Carcinoembryonic antigen (CEA), Squamous cell carcinoma
antigen (SCC), Needle aspiration biopsy (NAB), Tumor marker, Cytological fluid, Non-small cell lung cancer (NSCLC)Background
Lung cancer has the highest mortality of any cancer
worldwide and typically has a very poor prognosis. Lung
cancer survival and therapy largely depend on the dis-
ease histology and stage at diagnosis [1,2]. Therefore,
early diagnosis is paramount to improving prognosis. In* Correspondence: bchoi@yuhs.ac
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reproduction in any medium, provided the orclinical practice, diagnostic tools usually used for lung
cancer include computed tomography (CT), bronchos-
copy, and sputum analysis, which all have limitations for
early diagnosis of lung cancer. Therefore, biopsy with
histopathological examination is usually used to confirm
the diagnosis [2].
Percutaneous needle aspiration biopsy (NAB) of the
lung is a relatively safe and accurate method for diagnos-
ing lung lesions with a reported accuracy, ranging from
64% to 97%. Major complications are rare [3,4]; however,
transthoracic needle biopsy of lung lesions has a false
negative rate of up to 29% for diagnosis of malignancies. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sufficient tissue are not reliable for excluding malig-
nancy. Patients with these types of biopsy results should
have tissue re-sampling with biopsy or surgical resection,
or close clinical and imaging follow-up [5].
Serum tumor markers have been extensively studied in
lung cancer, but none are specific for detecting lung can-
cer. Several tumor markers, including cytokeratin 19
fragments (CYFRA 21–1), carcinoembryonic antigen
(CEA), and squamous cell carcinoma antigen (SCC),
have been investigated for diagnostic and prognostic
value in non-small cell lung cancer (NSCLC) [6-9]. Lung
cancer tumor markers are useful tools for the follow-up
of cancer patients, and are used mainly for monitoring
the efficacy of therapy and early detection of recurrence
[10-12]. One of the main drawbacks of serum tumor
markers is that high concentrations are usually found
only when the disease is at an advanced stage [13,14].
Therefore, clinically detecting a lung tumor at an early
stage with serum marker assays is difficult [13,15].
Novel biomarkers are urgently needed for early diag-
nosis and predicting treatment response and prognosis.
Many types of samples are possible for this purpose,
but cytological fluid from a NAB is obtained directly
from tumor tissue, therefore many biomarker candi-
dates will be present in high concentrations [16]. We
preformed an initial study on cytological tumor markers
that suggested additional evaluation of cytological
tumor markers CYFRA 21–1, CEA and SCC would be
valuable in improving sensitivity in diagnosis of NSCLC
in patients undergoing NAB. Our previous results
showed a significant increase in sensitivity and accuracy
for NAB combined with cytological CYFRA 21–1 com-
pared with NAB alone (100% versus 85.7%, p = 0.001;
97.8% versus 89%, p = 0.0209, respectively) [17]. We
conducted this external validation study to prospectivelyFigure 1 Flow chart of patient selection.assess and validate the tumor markers CYFRA 21–1,
CEA, and SCC in cytological fluid obtained from NAB
samples to determine if they improved the performance
of NAB for diagnosing NSCLC compared to serum
tumor markers.Methods
Patient selection
The external validation study protocol was approved by
the Institutional Review Boards and written informed
consent was obtained from all patients.
From November 1, 2009 to May 31, 2010, 249 patients
who had a suspicious pulmonary nodule or mass con-
cerning for lung malignancy on CT were prospectively
enrolled for the validation arm. The inclusion criteria
were age >20, lesion size more than 8 mm, and solid
lesions (ground glass opacity (GGO) component of less
than 50%). The exclusion criteria were: histologically-
confirmed small cell lung cancer or lymphoma (n = 7),
inconclusive pathological or cytological results (n = 17),
GGO lesions (n = 16), and refusal to provide written
informed consent (n = 15) (Figure 1).
Pre-biopsy evaluation included reviews of CT scans, la-
boratory studies, and medical records. All patients
underwent either CT-guided NAB or fluoroscopy-guided
NAB procedures, and all had NSCLC confirmed by hist-
ology and/or cytology. The final study population was
comprised of 128 men and 66 women, aged from 34 to
82 years (mean age, 63.7 years). Data collection was sys-
tematized and a standardized registration form was pre-
pared. For each patient, the following information was
recorded: age, sex, history, biopsy site, size of the lesion,
NAB results, pathology results, and laboratory data
(serum and cytological fluid tumor markers for CYFRA
21–1, CEA, and SCC).
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Three experienced chest radiologists who had four, six,
or ten years of experience performing thoracic biopsies
performed the biopsy procedures. Fluoroscopy-guided
biopsy interventions (n=52) were performed using a
fluoroscope (Medix 130, Hitachi Med. Corp, Japan) and
CT-guided biopsy interventions (n=142) were performed
using a 16-channel multi-detector CT (MDCT) (Soma-
tom Sensation 16, Siemens, Forchheim, Germany)
equipped with CARE-vision software. The exposure
parameters during CT-guided biopsy were 120 kV and
30 mA with a slice thickness of 6 mm. All procedures
were performed with patients in a prone, supine, or lat-
eral decubitus position, depending on the location of the
lesion. The puncture area was cleaned with an antiseptic
solution followed by administration of local anesthesia
via subcutaneous injection of 1% lidocaine (Xylocaine,
AstraZeneca). In all cases, more than two aspiration spe-
cimens were obtained to get enough specimen using 20–
22 gauge Chiba needles (Cook, Bloomington, IN, USA).
Cytological fluid was also aspirated during the procedure
without additional needle punctures. Both aspiration
specimens and cytological fluid were obtained with one
needle puncture. A part of each specimen was placed in
95% ethyl alcohol for cytological examination. The rest
of the specimen and fluid was prepared in tube for
evaluation of cytological tumor marker.
Cytological results were evaluated and divided into the
following diagnostic categories: ‘malignant’, ‘suspicious
for malignancy’, ‘negative for malignancy’, and ‘non-
diagnostic’ (e.g., cell paucity or samples with a few atypical
cells). A designation of ‘malignancy’ or ‘suspicious for ma-
lignancy’ was considered a positive result. A designation
of ‘negative for malignancy’ was considered a negative re-
sult. Non-diagnostic designations (n = 17) were consid-
ered neither positive nor negative, and the results were
excluded from the analysis.
Tumor marker analysis
Blood and cytological fluid were collected from each pa-
tient before any therapy. Serum and cytological fluid
supernatants were obtained by centrifugation at 2000g
for 10 min and stored at −40°C until tumor markers
were assayed using commercial immunoassay kits. For
both cytological fluid and serum, the technicians per-
forming the assays were blinded to the final diagnosis.
CYFRA 21–1 levels were measured using an electroche-
miluminescent immunoassay (ECLIA) (CYFRA 21–1;
Roche Diagnostics, Germany). CEA levels were mea-
sured using a chemiluminescence immunoassay (CLIA)
(Centaur CEA; Bayer HealthCare, USA). SCC levels were
measured using an immunoradiometric assay (IRMA)
(SCC-RIABEAD; SRL Inc., Japan). Tumor markers incytological fluid samples were assayed twice and mean
values used for analysis.
For serum tumor marker levels, upper limits of nor-
mality were 3.3 ng/mL for CYFRA 21–1, 5 ng/mL for
CEA and 2 ng/mL for SCC [18,19]. To the best of our
knowledge, no other study measuring cytological tumor
markers in NSCLC patients has been published. There-
fore, no reference normal values for cytological fluid
levels of various tumor markers were available. There-
fore, we used cut-off values for cytological tumor mar-
kers of 15.7 ng/mL for CYFRA 21–1, 0.6 ng/mL for
CEA, and 0.86 ng/mL for SCC [17]. In our previous
study, receiver operating characteristics (ROC) curves
were constructed using the values of tumor markers in
the cytological fluid and a cut-off value was determined
using the maximum Youden index for differentiation be-
tween malignant and benign lesions [17]. Any marker
higher than the cut-off value was considered positive.
Statistical analysis
A positive NAB result was considered a true-positive re-
sult if there was surgical confirmation, and a false-
positive result if no evidence of malignancy was found
during surgical resection (in the absence of preoperative
chemotherapy). Results were considered negative if no
tumor was identified during examination of the surgical
specimen or regression was found on subsequent CT.
Surgical confirmation of malignancy in the lesion with a
negative NAB result was considered a false-negative
finding.
Differences between the two groups (malignant and
benign groups) were evaluated using the chi-square test
or Fisher’s exact test. Sensitivity, specificity, accuracy,
positive predictive value (PPV), and negative predictive
value (NPV) of NAB alone and NAB combined with
serum or cytological tumor markers (CYFRA21-1, CEA,
and SCC) were calculated. When analyzing the diagnos-
tic yield of a combination of tumor markers, a case was
considered positive if either tumor marker or NAB result
was positive, and negative if both tumor marker and
NAB results were negative. Comparisons were made
using weighted least squares (WLS) for statistical signifi-
cance of sensitivity and accuracy between NAB com-
bined with tumor markers and NAB alone [20]. To
compare the performance of NAB alone and NAB com-
bined with tumor markers, ROC curves were con-
structed and the area under the curve (AUC) was
compared. Comparisons were made using the Delong
method for statistical significance of AUC [21]. Statis-
tical analyses were performed with SAS software (ver-
sion 9.2 for Windows; SAS Institute, Cary, NC, USA)
and p-values were adjusted using Bonferroni’s correc-
tion with less than 0.05 were considered statistically
significant.
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Among 194 patients, 139 patients (71.6%) had NSCLC
and 55 (28.4%) patients had benign lesions. Table 1 sum-
marizes patient characteristics. Histologic NSCLC types
by patient and according to the WHO classifications
were as follows [22]: 92 patients (66.2%) with adenocar-
cinoma (AC), 29 (20.8%) with squamous cell carcinoma
(SQ), 3 (2.2%) with large-cell carcinoma, and 15 (10.8%)
with NSCLC not otherwise specified (NOS). Of the 55
benign lesions, 29 were eventually diagnosed as benign
based on progressive CT scans that showed lesion re-
gression. Except for biopsy method and tuberculosis, all
other characteristics, including age, sex, history of hyper-
tension or diabetes, and smoking status were not signifi-
cantly different between the two groups (p > 0.05).
The serum and cytological fluid levels of CYFRA 21–
1, CEA, and SCC are presented in Table 2. CEA and
SCC serum levels were significantly higher in the malig-
nant group than in the benign group (p = 0.022, and p =
0.035, respectively). In the cytological fluid, CYFRA 21–1,
CEA and SCC were significantly higher in the malignant
group than in the benign group (p = 0.001, p = 0.003, and
p = 0.027, respectively).
Table 3 describes the sensitivity, specificity, accuracy,
PPV and NPV of NAB alone and NAB combined with
serum or cytological tumor markers in 194 patients.
Sensitivity and accuracy were not significantly different
between NAB combined with serum tumor markers and
NAB alone (for all three serum tumor markers, p > 0.05).
However, sensitivity increased significantly for NAB com-
bined with cytological tumor markers compared withTable 1 Demographic and baseline characteristics of 194 pati
Characteristics All (n=194) Malig
Sex
Male 128(65.9)
Female 66(34.1)
Age (years) a 63.7±10.4
Lesion Size (mm) a 30.9±17.8
Location
Upper/Middle lobe 129(66.5)
Lower lobe 65(33.5)
Method
CT-guidence 142(73.1)
Fluoro-guidence 52(26.9)
Past history
Smoking 104(53.6)
Hypertension 85(43.8)
Diabetes 25(12.8)
Pulmonary Tuberculosis 30(15.4)
Note-Values in parentheses are percentages. aData are presented as mean ± standaNAB alone (CYFRA 21–1: 95% versus 83.5%, p < 0.001,
CEA: 92.1% versus 83.5%, p = 0.002, and SCC: 91.4% ver-
sus 83.5%, p = 0.003). Accuracy improved significantly for
NAB combined with cytological CYFRA 21–1 compared
with NAB alone (95.9% versus 88.1%, p < 0.001). However,
accuracy was not significantly different between NAB
combined with cytological CEA or SCC and NAB alone
(p = 0.138 and p > 0.999, respectively).
For diagnosis of NSCLC, the AUC of NAB with serum
CEA and SCC was not significantly larger than the AUC
of NAB alone (p = 0.408, and p = 0.207, respectively).
The AUC of NAB with serum CYFRA 21–1 decreased
significantly compared with the AUC of NAB alone
(p = 0.009). Using the cytological tumor markers, the
AUC of NAB with cytological CYFRA 21–1 was signifi-
cantly larger than the AUC of NAB alone (0.966 versus
0.917, p = 0.009). However, the AUC of NAB with cyto-
logical CEA was not significantly larger than the AUC of
NAB alone (p = 0.999). The AUC of NAB with cytological
SCC decreased significantly compared with the AUC of
NAB alone (p = 0.003) (Table 4) (Figure 2).
Among the 139 malignant lesions, there were 42 cases
of stage 1, 13 cases of stage 2, 16 cases of stage 3 and 68
cases of stage 4, respectively. In early stage (stage 1 and
2), the sensitivity and accuracy were not significantly dif-
ferent between NAB alone and NAB combined with
serum tumor markers (for all three serum tumor mar-
kers, p > 0.05). However, sensitivity increased signifi-
cantly for NAB combined with a cytological tumor
marker compared with NAB alone (CYFRA 21–1: 94.4%
versus 75.9%, p = 0.006, CEA: 87% versus 75.9%, p =ents
nant (n=139) Benign (n=55) p-value
0.811
91(65.5) 37(67.2)
48(34.5) 18(32.8)
64.6±10.1 62.7±11.6 0.236
32.2±21.2 27.8±14.9 0.162
0.385
95(68.3) 34(61.8)
44(31.7) 21(38.2)
0.039
96 (69.1) 46(83.6)
43(30.9) 9(16.4)
74 (53.2) 30(54.5) 0.869
59(42.4) 26(47.2) 0.283
20(14.3) 5(9.1) 0.321
16(11.5) 14(25.4) 0.015
rd deviation.
Table 2 Serum and Cytological Fluid Levels for CTFRA 21–1, CEA, and SCC in 194 Patients with Malignant and Benign
Lesions
Tumor marker Malignant (n=139) Benign (n=55) p-value
Serum
CYFRA 21–1 (ng/mL) 8.36 ± 26.87 2.30 ± 1.23 0.097
CEA (ng/mL) 31.86 ± 93.37 2.67 ± 1.87 0.022
SCC (ng/mL) 1.22 ± 1.48 0.78 ± 0.62 0.035
Cytological fluid
CYFRA 21–1 (ng/mL) 111.04 ± 159.59 5.01 ± 3.55 0.001
CEA (ng/mL) 20.63 ± 75.50 0.31 ± 0.48 0.003
SCC (ng/mL) 13.14 ± 33.76 2.84 ± 7.82 0.027
Note-Data are presented as mean ± standard deviation.
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ively). Accuracy improved significantly for NAB com-
bined with cytological CYFRA 21–1 compared with
NAB alone (96.3% versus 88.1%, p = 0.021). In advanced
stage (stage 3 and 4), the sensitivity and accuracy were
not significantly different between NAB alone and NAB
combined with serum tumor markers (for all three
serum tumor markers, p > 0.05). However, sensitivity
increased significantly for NAB combined with a cyto-
logical tumor marker compared with NAB alone
(CYFRA 21–1: 95.2% versus 88.1%, p = 0.042, CEA:
95.2% versus 88.1%, p = 0.042, respectively). The accur-
acy was not significantly different between NAB alone
and NAB combined with cytological tumor markers (for
all three tumor markers, p > 0.05) (Table 5).
In the results of subgroup analysis for diagnosing
adenocarcinoma (n=92), the sensitivity and accuracy
were not significantly different between NAB alone and
NAB combined with serum tumor markers (for all three
serum tumor markers, p > 0.05). However, sensitivity
increased significantly for NAB combined with a cyto-
logical tumor marker compared with NAB alone
(CYFRA 21–1: 92.4% versus 79.3%, p = 0.003, CEA:
89.1% versus 79.3%, p = 0.009, respectively). AccuracyTable 3 Comparison of Diagnostic Results of NAB alone and N
Diagnostic Method Sensitivity (%) Specificity (%
NAB alone 83.5 10
NAB+Serum Tumor marker
CYFRA (3.3) 85.6 8
CEA (5) 86.3 9
SCC (2) 84.2 9
NAB+Cytological Tumor marker
CYFRA (15.7) 95.0 9
CEA (0.6) 92.1 9
SCC (0.86) 91.4 7
Note-Numbers in parentheses are cut-off levels of tumor markers in ng/mL.
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CEA, c
fragments; NAB, needle aspiration biopsy.improved significantly for NAB combined with cyto-
logical CYFRA 21–1 compared with NAB alone (94.6%
versus 87.1%, p = 0.006). In the results of subgroup ana-
lysis for diagnosing squamous cell carcinoma (n=29), the
sensitivity and accuracy of NAB combined with any
serum or cytological tumor marker were not signifi-
cantly higher than NAB alone (for all serum and cyto-
logical tumor markers, p > 0.05) (Table 6).Discussion
This study was designed to determine whether analysis
of the tumor markers CYFRA 21–1, CEA, and SCC in
cytological fluid could improve the performance of NAB
in the diagnosis of NSCLC. Our external validation
study showed that NAB with additional evaluation of
cytological tumor marker of CYFRA 21–1 can improve
sensitivity and accuracy in the diagnosis for NSCLC.
Early diagnosis of lung cancer is essential for increased
survival, but this is difficult because the symptoms are
non-specific and are frequently found in the risk group
of smoker patients. In clinical practice, lung cancer diag-
nosis still depends primarily on imaging techniques,
such as x-ray and CT, and if a suspicious lesion isAB combined with Tumor Markers in 194 Patients
) Accuracy(%) PPV (%) NPV (%)
0.0 88.1 100.0 70.5
1.8 84.5 92.2 69.2
0.9 87.6 96.0 72.5
2.7 86.6 96.7 69.9
8.2 95.9 99.2 88.5
2.7 92.3 97.0 82.3
0.9 85.6 88.8 76.5
arcinoembryonic antigen; SCC, squamous cell carcinoma; CYFRA, cytokeratin 19
Table 4 Comparison of Diagnostic Performance of NAB
alone and NAB with Tumor Markers in 194 patients
Tumor marker AUC P-value
NAB alone 0.917 (95%CI;0.886-0.948)
NAB with Serum tumor marker
CYFRA (3.3) 0.837 (95%CI;0.778-0.896) 0.009
CEA (5) 0.886 (95%CI;0.838-0.934) 0.408
SCC (2) 0.885 (95%CI;0.838-0.901) 0.207
NAB with Cytological tumor marker
CYFRA (15.7) 0.966 (95%CI;0.940-0.991) 0.009
CEA (0.6) 0.924 (95%CI;0.883-0.965) 0.999
SCC (0.86) 0.811 (95%CI;0.746-0.876) 0.003
Note-Numbers in parentheses are cut-off levels of tumor markers in ng/mL
Abbreviations: PPV, positive predictive value; NPV, negative predictive value;
CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma; CYFRA,
cytokeratin 19 fragments; NAB, needle aspiration biopsy; AUC, areas under the
curve.
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used to confirm the diagnosis.
Currently, transthoracic NAB is often performed to
obtain a definitive diagnosis and is a useful procedure
for diagnosing pulmonary nodules that are highly likely
to be malignant, especially in patients who are not can-
didates for surgery [5]. Although NAB of the lung is a
relatively safe and accurate method for diagnosing lung
lesions, the results of transthoracic needle biopsy of lung
lesions often results in false negative in the diagnosis of
malignancy, and non-specific results are common in
NAB [5]. Previous reports found that, transthoracic nee-
dle biopsy of lung lesions has a false negative rate of up
to 29% for malignancy diagnosis [4,5], and 27% of the
non-specific results are reported to later turn out to be
malignant [23]. Therefore, patients with suspected lungFigure 2 Receiver operating characteristics (ROC) curves. (a) ROC curv
NAB alone. (b) ROC curves for NAB combined with CYFRA 21–1, CEA and Smalignancy but inconclusive results on initial lung bi-
opsy often require a second transthoracic lung biopsy or
surgical biopsy including video-assisted thoracoscopic
surgery (VATS).
Currently, several tumor markers in the serum have
been extensively studied in lung cancer, but none is spe-
cific for diagnosis of NSCLC. Tumor markers may aid in
clinical diagnosis as well as prognosis and follow-up.
Tumor marker determination is a simple, inexpensive
test, available in most centers where lung cancer is diag-
nosed. However, the results to date do not support the
widespread use of tumor markers for diagnosis.
We used cytological fluid obtained by biopsy as a new
type of sample for tumor marker analysis. We hypothe-
sized that cytological fluid obtained from NAB has the
potential to be an effective sample, as it is obtained dir-
ectly from tumor tissue, and because many biomarkers
candidates will exist in high concentrations [16]. Al-
though lung cancer tissue biopsy is invasive, biopsy and
resection are currently the gold standards for confirma-
tive diagnosis, and thus are generally performed in cases
of high suspicion of malignancy. Furthermore, perform-
ing the extra step of measuring concentrations of tumor
markers in the fluid that is aspirated does not require an
additional puncture, takes little extra time, and is easy.
Results from our previous study indicated that add-
itional evaluation of tumor markers in the cytological
fluid can improve the diagnostic performance of CT-
guided NAB in NSCLC patients. Our previous results
showed a significant increase in sensitivity and accuracy
for NAB combined with CYFRA 21–1 compared with
NAB alone (100% versus 85.7%, p = 0.001; 97.8% versus
89%, p = 0.0209, respectively) [17]. This was supported
by the results of this validation study. When wees for NAB combined with CYFRA 21–1, CEA and SCC in the serum and
CC in the cytological fluid and NAB alone.
Table 5 Comparison of Diagnostic Results of NAB alone and NAB combined with Tumor Markers according to tumor
stage
Diagnostic Method Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%)
Early Stage (Stage 1 and 2, n=55)
NAB alone 75.9 100 88.1 100 80.9
NAB+Serum Tumor marker
CYFRA (3.3) 77.8 81.8 79.8 80.8 78.9
CEA (5) 75.9 90.9 83.5 89.1 79.4
SCC (2) 75.9 92.7 84.4 91.1 79.7
NAB+Cytological Tumor marker
CYFRA (15.7) 94.4 98.2 96.3 98.1 94.7
CEA (0.6) 87 92.7 89.9 92.2 87.9
SCC (0.86) 87 70.9 78.9 74.6 84.8
Advanced Stage (Stage 3 and 4, n=84)
NAB alone 88.1 100 92.8 100 84.6
NAB+Serum Tumor marker
CYFRA (3.3) 90.5 81.8 87.1 88.4 84.9
CEA (5) 92.9 90.9 92.1 94 89.3
SCC (2) 89.3 92.7 90.6 94.9 85
NAB+Cytological Tumor marker
CYFRA (15.7) 95.2 98.2 96.4 98.8 93.1
CEA (0.6) 95.2 92.7 94.2 95.2 92.7
SCC (0.86) 94 70.9 84.9 83.2 88.6
Note-Numbers in parentheses are cut-off levels of tumor markers in ng/mL.
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma; CYFRA, cytokeratin 19
fragments; NAB, needle aspiration biopsy.
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ity and accuracy were not significantly different between
NAB combined with serum tumor markers and NAB
alone (for all three serum tumor markers, p > 0.05).
However, sensitivity increased significantly for NAB
combined with any cytological tumor marker compared
to NAB alone (95% for CYFRA 21–1, p < 0.001; 92.1%
for CEA p = 0.002; and 91.4% for SCC, p = 0.003). The
accuracy improved significantly for NAB combined with
cytological CYFRA 21–1 compared with NAB alone
(95.9% versus 88.1%, p < 0.001). When we compared the
AUC between NAB combined with tumor markers and
NAB alone, the AUC of NAB with cytological CYFRA
was significantly larger than the AUC of NAB alone
(0.966 versus 0.917, p = 0.009). Furthermore, in sub-
group analysis, the sensitivity also increased significantly
for NAB combined with any cytological tumor markers
compared with NAB alone in early stage lung cancer.
This indicated that this cytological tumor marker had
additional value in the diagnosis of NSCLC. According
to our validation study, NAB combined with cytological
CYFRA 21–1 had the best diagnostic performance, simi-
lar to findings of previous studies [6,10]. CYFRA is the
most sensitive tumor marker for NSCLC. Wieskopf et al.[20] reported that serum CYFRA 21–1 was a sensitive
and specific tumor marker for NSCLC diagnosis, appear-
ing more sensitive and more specific than other tumor
markers such as CEA and SCC.
In the results of subgroup analysis according to histo-
logical cell types, the sensitivity and accuracy of NAB
combined with cytological CYFRA 21–1 was signifi-
cantly higher than NAB alone for diagnosing adenocar-
cinoma. Although CYFRA is one of the most sensitive
tumor markers available, its relationship with specific
histology is controversial. Some studies reported that
CYFRA has no clear relationship to different histological
cell subtypes in NSCLC, whereas, others have reported
that CYFRA is a more sensitive and specific tumor mar-
ker especially for the squamous cell subtype [6,10,20].
Previous studies using immunohistochemical analysis for
resected adenocarcinoma and squamous cell carcinoma,
showed that cytokeratin-19, the marker used for
CYFRA21-1, stained both adenocarcinoma and squa-
mous cell carcinoma strongly and indiscriminately [24]
[25]. Although NAB combined with cytological CYFRA
21–1 had tendency to increase sensitivity and accuracy
for diagnosing squamous cell carcinoma subtype, the
sensitivity and accuracy were not significantly different
Table 6 Comparison of Diagnostic Results of NAB alone and NAB combined with Tumor Markers according to
histological subtype
Diagnostic Method Sensitivity(%) Specificity(%) Accuracy(%) PPV (%) NPV (%)
Adencarcinoma subtype (n=92)
NAB alone 79.3 100 87.1 100 74.3
NAB+Serum Tumor marker
CYFRA (3.3) 81.5 81.8 81.6 88.2 72.6
CEA (5) 81.5 90.9 85 93.8 74.6
SCC (2) 79.3 92.7 84.4 94.8 72.9
NAB+Cytological Tumor marker
CYFRA (15.7) 92.4 98.2 94.6 98.8 88.5
CEA (0.6) 89.1 92.7 90.5 95.3 83.6
SCC (0.86) 83.5 70.9 81.6 88 78
Squamous cell carcinoma subtype (n=29)
NAB alone 89.7 100 96.4 100 94.8
NAB+Serum Tumor marker
CYFRA (3.3) 93.1 81.8 85.7 73 95.7
CEA (5) 93.1 90.9 91.7 84.4 96.2
SCC (2) 93.1 92.7 92.9 87.1 96.2
NAB+Cytological Tumor marker
CYFRA (15.7) 100 98.2 98.8 96.7 100
CEA (0.6) 96.6 92.7 94 87.5 98.1
SCC (0.86) 100 70.9 81 64.4 100
Note-Numbers in parentheses are cut-off levels of tumor markers in ng/mL.
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CEA, carcinoembryonic antigen; SCC, squamous cell carcinoma; CYFRA, cytokeratin 19
fragments; NAB, needle aspiration biopsy.
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CYFRA 21–1. This may be explained in that the sample
size for squamous cell carcinoma subtype was small. In
our study, more than half of the cases were adenocarcin-
omas, and only 20% were squamous cell carcinomas.
Based on our validation study, cytological fluid could
be an effective sample for tumor markers and may be
clinically useful in lung cancer diagnosis. This is because
while lung biopsy using needle aspiration is a confirma-
tive method for lung cancer diagnosis, 29% of NAB
results can be non-diagnostic [18,19]. Taking the extra
step of measuring tumor markers concentrations in the
aspirated fluid does not require an additional puncture,
takes little extra time, and is easy to perform. Therefore,
we believe that in cases of suspicious malignant nodules
or masses showing a negative or inconclusive cytological
result, determining tumor markers in the cytological
fluid may be a helpful complementary tool for lung can-
cer diagnosis.
Our study has some limitations. First, the major two
histologic types were not represented equally. More than
half of the cases were adenocarcinomas, and only 20%
were squamous cell carcinomas. Furthermore, in sub-
group analysis, the sensitivity increased significantly forNAB combined with cytological tumor markers (CYFRA
21–1 and CEA) compared with NAB alone in the diag-
nosis of adenocarcinoma, whereas, the sensitivity and ac-
curacy were not significantly different between NAB
alone and NAB combined with any serum or cytological
tumor markers for diagnosing squamous cell carcinoma.
Therefore, the value of cytological tumor markers deter-
mined in this study might be limited for cell types other
than adenocarcinoma. Second, the results may be influ-
enced by the method used to choose the cut-off point.
Although serum tumor markers have normal reference
values, no reference normal values are available for cyto-
logical fluid levels of the tumor markers. In this study,
we used the cut-off values for cytological tumor markers
determined in our previous study to validate the cut-off
values selected for tumor markers as an independent
series. In our previous study, ROC curves were con-
structed using tumor marker values in the cytological
fluid and a cut-off value was determined using the max-
imum Youden index for differentiation between malig-
nant and benign lesions. Third, while most lesions had
histopathologically confirmed diagnoses, 29 lesions
required follow-up imaging studies and clinical examina-
tions; the follow-up time used to classify lesions as
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lesion regression.
Conclusion
In conclusion, among the tumor markers studied, CYFRA
21–1 measurements in cytological fluid improved the
diagnostic performance of percutaneous NAB for NSCLC.
Our results provide a rationale for evaluating tumor mar-
kers in cytological fluid as complementary to NAB for
lung cancer diagnosis. Therefore, in cases of suspicious
malignant nodules or masses showing a negative or incon-
clusive cytological result, determining tumor markers in
cytological fluid may be helpful for lung cancer diagnosis.
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